Tempus Launches Automated Active Follow-Up Service to Improve Guideline-Based Patient Care

Author : Lennon Ross | Published On : 15 Apr 2026

Tempus AI, Inc. has unveiled a new automated active follow-up service designed to support guideline-concordant patient care and strengthen precision medicine workflows. This advanced solution places patients on a dynamic care pathway while continuously updating clinicians through the Hub portal, a secure AI-powered physician platform that delivers context-aware alerts in real time.

One of the biggest challenges in modern healthcare is that genomic reports can quickly become outdated. Regulatory approvals and clinical guidelines evolve rapidly, and patient conditions often change during treatment. To address this issue, Tempus has developed a system that ensures clinical insights remain continuously relevant.

The automated service proactively surfaces updated therapy recommendations whenever new clinical guidelines are introduced or innovative treatments become available. Importantly, these updates do not require additional patient samples. This allows clinicians to rely on up-to-date genomic insights, enabling more accurate, evidence-based decisions throughout a patient’s care journey.

In today’s fast-moving oncology landscape, the gap between genomic sequencing and drug approvals continues to widen. Treatments are often approved after initial sequencing is completed, leaving potential therapeutic opportunities untapped. Tempus’ active follow-up service acts as a clinical safety net, bridging this gap and ensuring that actionable insights remain accessible.

By transforming static genomic reports into continuously evolving clinical resources, the solution empowers physicians to stay aligned with the latest advancements in precision medicine. As a result, patients benefit from more timely and personalized treatment strategies.

According to Ezra Cohen, Chief Medical Officer of Oncology at Tempus, the pace of innovation in cancer care is accelerating rapidly. He emphasized that this service was developed to keep up with evolving treatments and approvals, ensuring that genomic insights remain actionable long after initial testing.

Discover Health Tech Insiders for the latest advancements in medical technology and trusted strategic insights shaping the future of tech-driven healthcare transformation.